|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300075760 |
|
最近更新日期: Date of Last Refreshed on: |
2023-09-14 15:46:48 |
|
注册时间: Date of Registration: |
2023-09-14 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
清热化痰活血方法稳定高血压病患者肾动脉易损斑块的临床研究 |
|
Public title: |
Clinical study on stabilizing vulnerable plaque of renal artery in patients with hypertension by Chinese Herbs of QingReHuaTanHuoXue |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
清热化痰活血方法稳定高血压病患者肾动脉易损斑块的临床研究 |
|
Scientific title: |
Clinical study on stabilizing vulnerable plaque of renal artery in patients with hypertension by Chinese Herbs of QingReHuaTanHuoXue |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
程文立 |
研究负责人: |
程文立 |
|
Applicant: |
wenli Cheng |
Study leader: |
Wenli Cheng |
|
申请注册联系人电话: Applicant telephone: |
+86 136 1118 9837 |
研究负责人电话: Study leader's telephone: |
+86 136 1118 9837 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chengwenli2000@163.com |
研究负责人电子邮件: Study leader's E-mail: |
chengweli2000@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区安贞路2号,首都医科大学附属北京安贞医院 |
研究负责人通讯地址: |
北京市朝阳区安贞路2号,首都医科大学附属北京安贞医院 |
|
Applicant address: |
No 2, AnZhen Road, ChaoYang District, BeiJing |
Study leader's address: |
No 2, AnZhen Road, ChaoYang District, BeiJing |
|
申请注册联系人邮政编码: Applicant postcode: |
100020 |
研究负责人邮政编码: Study leader's postcode: |
100020 |
|
申请人所在单位: |
首都医科大学附属北京安贞医院 |
||
|
Applicant's institution: |
Beijing Anzhen Hospital |
||
|
研究负责人所在单位: |
首都医科大学附属北京安贞医院 |
||
|
Affiliation of the Leader: |
Beijing Anzhen Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021163X |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京安贞医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Beijing Anzhen Hospital affiliated to Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-04-28 00:00:00 |
||
|
伦理委员会联系人: |
吴朝阳 |
||
|
Contact Name of the ethic committee: |
Chaoyang Wu |
||
|
伦理委员会联系地址: |
首都医科大学附属北京安贞医院 |
||
|
Contact Address of the ethic committee: |
Beijing Anzhen Hospital |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6445 6214 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京安贞医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Capital Medical Development Fund |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区安贞路2号,北京安贞医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Beijing Municipal Health and Health Commission |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
首都医学发展基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Capital Medical Development Fund |
||||||||||||||||||||||
|
Target disease: |
Hypertension ,Renal atherosclerosis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
中药清热化痰方法稳定高血压合并肾动脉易损斑块 |
||||||||||||||||||||||
|
Objectives of Study: |
The method of clearing heat and eliminating phlegm with traditional Chinese medicine stabilised hypertension complicated with vulnerable plaque of renal artery |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
具有肾动脉部位动脉粥样硬化性易损斑块的原发性高血压病患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients with essential hypertension who have atherosclerotic vulnerable plaques in the renal artery. |
||||||||||||||||||||||
|
排除标准: |
继发性高血压,肾性高血压、先天性纤维肌性发育不良性高血压、主动脉缩窄性高血压、大动脉炎引起的高血压、嗜铬细胞瘤、库欣氏综合征、原发性醛固酮增高症性高血压、睡眠呼吸暂停综合征相关高血压、肾动脉狭窄导致的高血压(即肾动脉狭窄>50%的患者)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Secondary hypertension, renal hypertension, congenital fibromuscular dysplasia hypertension, aortic coaccotion hypertension, aortitis induced hypertension, pheochromocytoma, Cushing's syndrome, primary aldosterone elevation induced hypertension, sleep apnea syndrome associated hypertension, hypertension caused by renal artery stenosis (i.e. patients with renal artery stenosis>50%) . |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-04-01 00:00:00至 To 2024-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-06-22 00:00:00 至 To 2024-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲,盲终点 |
|
Blinding: |
Single blind, blind endpoint |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
Resman |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Resman |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集使用北京安贞医院的HIS 系统,数据管理使用专业数据管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
HIS system of Beijing Anzhen Hospital was used for data collection, and professional data management system was used for data management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |